These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 1854661)
1. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Zehender M; Hohnloser S; Just H Cardiovasc Drugs Ther; 1991 Apr; 5(2):515-30. PubMed ID: 1854661 [TBL] [Abstract][Full Text] [Related]
2. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Shantsila E; Watson T; Lip GY Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322 [TBL] [Abstract][Full Text] [Related]
3. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes. Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411 [TBL] [Abstract][Full Text] [Related]
4. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. Jacobson I; Carlsson L; Duker G J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633 [TBL] [Abstract][Full Text] [Related]
5. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Shah RR; Hondeghem LM Heart Rhythm; 2005 Jul; 2(7):758-72. PubMed ID: 15992736 [TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic drugs and torsade de pointes. Lazzara R Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758 [TBL] [Abstract][Full Text] [Related]
7. [Lengthening of QT interval by antipsychotic drugs]. Haverkamp W; Deuschle M Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325 [TBL] [Abstract][Full Text] [Related]
8. Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia. Gillis AM Prog Cardiovasc Dis; 2000; 42(5):385-96. PubMed ID: 10768315 [TBL] [Abstract][Full Text] [Related]
9. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029 [TBL] [Abstract][Full Text] [Related]
10. [Risk management of QT-prolonging drugs by community pharmacists using a mobile electrocardiograph]. Shinozaki K Yakugaku Zasshi; 2010 Nov; 130(11):1597-601. PubMed ID: 21048421 [TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. Singh BN; Wadhani N J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women. Démolis JL; Strabach S; Vacheron F; Funck-Brentano C Br J Clin Pharmacol; 2005 Aug; 60(2):120-7. PubMed ID: 16042664 [TBL] [Abstract][Full Text] [Related]
16. Clinical types of proarrhythmic response to antiarrhythmic drugs. Bigger JT; Sahar DI Am J Cardiol; 1987 Apr; 59(11):2E-9E. PubMed ID: 3554950 [TBL] [Abstract][Full Text] [Related]
17. Drug-induced proarrhythmic effects: assessment of changes in QT interval. Sheridan DJ Br J Clin Pharmacol; 2000 Oct; 50(4):297-302. PubMed ID: 11012551 [No Abstract] [Full Text] [Related]